Home Stocks Acadia gains Fast Track status for remlifanserin in Alzheimer’s disease psychosis

Acadia gains Fast Track status for remlifanserin in Alzheimer’s disease psychosis

by Deidre Salcido
0 comments
Image 1392468388.jpg

BeritK/iStock via Getty Images

  • The US FDA has granted Fast Track designation to Acadia Pharmaceuticals’ (ACAD) remlifanserin in Alzheimer’s disease psychosis.
  • The asset is currently in phase 2 for Lewy body dementia with psychosis.
  • Remlifanserin is a selective, 5-HT2A receptor inverse agonist.

You may also like

Leave a Comment

About Us

Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stockscryptocurrencyreal estate, finance, and much more.

© 2025 AI Investor Picks – All Rights Reserved

AI Investor Picks